# RCKT catalysts: ROCKET PHARMACEUTICALS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/rckt/catalysts

> ROCKET PHARMACEUTICALS, INC. (RCKT) has 4 upcoming catalysts. The next is the MID-2028 topline data readout, mid-2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for RCKT?

ROCKET PHARMACEUTICALS, INC. (RCKT) has 4 upcoming catalysts. The next is the MID-2028 topline data readout, mid-2028. Press release filed with the SEC (EX-99): "Rocket expects to complete pivotal trial dosing by mid-2027, with topline results anticipated in mid-2028." [Calendar and source filings](https://sec-api.dev/companies/rckt/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001140361-26-043434, https://www.sec.gov/Archives/edgar/data/1281895/000114036126043434/ef20085455_ex99-1.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/rckt/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | ROCKET PHARMACEUTICALS, INC. |
| Ticker | RCKT (Nasdaq) |
| SEC CIK | 1281895 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/rckt |

## Cash runway

Cash $279.4M as of 2026-09-30; quarterly burn $39.1M; about 21.5 months of runway at that rate (XBRL company facts, accession 0001193125-26-458320).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2023 | [ROCKET PHARMACEUTICALS, INC. complete response letter (CRL)](https://sec-api.dev/companies/rckt/catalysts) | RCKT | severe LAD-I | completed, complete response letter | "In September 2023, the FDA accepted the Biologics License Application (BLA) and granted priority review for RP-L201 for the treatment of severe LAD-I. In June 2024, the Company announced that the FDA had issued a CRL in response to the BLA wherein the FDA requested limited additional CMC information to complete its review." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1281895/000095017025066898/rckt-20250331.htm)) |
| March 31, 2024 | [ROCKET PHARMACEUTICALS, INC. PDUFA date](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | scheduled | "In September 2023, A BLA filing for RP-L201 was accepted by the FDA with priority review with an initial PDUFA date of March 31, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1281895/000095017025104996/rckt-20250630.htm)) |
| Jun 2024 | [ROCKET PHARMACEUTICALS, INC. complete response letter (CRL)](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed, complete response letter | "In June 2024, we announced that the FDA issued a CRL in response to the BLA wherein the FDA requested limited additional CMC information to complete its review." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm)) |
| June 14, 2024 | [Rocket complete response letter (CRL)](https://sec-api.dev/pdufa/rocket) | RCKT |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 06/14/2024 for BL 125806 to Rocket Pharmaceuticals, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125806_20240614.pdf%22)) |
| February 27, 2025 | [ROCKET PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed | "Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036125006302/ef20044486_ex99-1.htm)) |
| May 2025 | [KRESLADI (marnetegragene autotemcel) interim data readout](https://sec-api.dev/pdufa/marnetegragene-autotemcel) | RCKT |  | scheduled | "Initial data from the Phase 1 study of RP-A601 for PKP2-ACM anticipated May 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/ef20048651_ex99-1.htm)) |
| May 8, 2025 | [ROCKET PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed | "Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/ef20048651_ex99-1.htm)) |
| August 4, 2025 | [ROCKET PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed | "Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036125029582/ef20053509_ex99-1.htm)) |
| October 14, 2025 | [KRESLADI (marnetegragene autotemcel) NDA/BLA acceptance](https://sec-api.dev/pdufa/marnetegragene-autotemcel) | RCKT |  | completed | "On October 14, 2025, Rocket Pharmaceuticals, Inc. (the "Company") announced that the U.S. Food and Drug Administration (the "FDA") has accepted resubmission of the Biologics License Application (BLA) for KRESLADI™ (marnetegragene autotemcel; marne-cel), a lentiviral vector (LV)-based investigational gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I), a rare genetic immune disorder that predisposes patients to recurrent and fatal infections and is near-uniformly fatal in childhood without an allogeneic hematopoietic stem cell transplant." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1281895/000114036125038030/ef20057000_8k.htm)) |
| November 6, 2025 | [ROCKET PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed | "Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036125040774/ef20058531_ex99-1.htm)) |
| February 26, 2026 | [ROCKET PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed | "Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/ef20066645_ex99-1.htm)) |
| March 26, 2026 | [KRESLADI (marnetegragene autotemcel) FDA approval](https://sec-api.dev/pdufa/marnetegragene-autotemcel) | RCKT |  | completed, approved | "Rocket Pharmaceuticals Announces FDA Approval of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126011573/ef20069038_ex99-1.htm)) |
| March 28, 2026 | [KRESLADI (marnetegragene autotemcel) PDUFA date](https://sec-api.dev/pdufa/marnetegragene-autotemcel) | RCKT |  | completed, approved | "KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/ef20066645_ex99-1.htm)) |
| March 28, 2026 | [ROCKET PHARMACEUTICALS, INC. PDUFA date](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | scheduled | "In October 2025, the FDA accepted the Company's resubmission of the BLA and assigned a PDUFA date of March 28, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1281895/000119312526458320/rckt-20260930.htm)) |
| mid-2026 | [KRESLADI (marnetegragene autotemcel) trial start](https://sec-api.dev/pdufa/marnetegragene-autotemcel) | RCKT |  | scheduled | "Dosing of the first patient is anticipated in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126019573/ef20072739_ex99-1.htm)) |
| May 2026 | [Rp-l102 primary completion](https://sec-api.dev/pdufa/rp-l102) | RCKT | Fanconi Anemia Complementation Group A | delayed | "NCT04248439 (Gene Therapy for Fanconi Anemia, Complementation Group A): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-05 (ESTIMATED); Lead Sponsor Rocket Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04248439)) |
| May 7, 2026 | [ROCKET PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed | "Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126019573/ef20072739_ex99-1.htm)) |
| August 10, 2026 | [ROCKET PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed | "Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126032028/ef20079821_ex99-1.htm)) |
| November 12, 2026 | [ROCKET PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed | "Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126043434/ef20085455_ex99-1.htm)) |
| mid-2028 | [MID-2028 topline data readout](https://sec-api.dev/pdufa/mid-2028) | RCKT |  | scheduled | "Rocket expects to complete pivotal trial dosing by mid-2027, with topline results anticipated in mid-2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126043434/ef20085455_ex99-1.htm)) |
| June 2028 | [Rp-a501 primary completion](https://sec-api.dev/pdufa/rp-a501) | RCKT | Danon Disease | scheduled | "NCT06092034 (A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Rocket Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06092034)) |
| Jun to Sep 2028 | [Rp-a501 topline data readout](https://sec-api.dev/pdufa/rp-a501) | RCKT | Danon Disease | scheduled | "NCT06092034 (A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Rocket Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06092034)) |
| January 2029 | [Rp-l301 primary completion](https://sec-api.dev/pdufa/rp-l301) | RCKT | Pyruvate Kinase Deficiency | delayed | "NCT06422351 (Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency): Overall Status SUSPENDED; Phase PHASE2; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Rocket Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06422351)) |

## Drugs

- [KRESLADI (marnetegragene autotemcel)](https://sec-api.dev/pdufa/marnetegragene-autotemcel): 
- [MID-2028](https://sec-api.dev/pdufa/mid-2028): 
- [Rocket](https://sec-api.dev/pdufa/rocket): 
- [Rp-a501](https://sec-api.dev/pdufa/rp-a501): Danon Disease
- [Rp-l102](https://sec-api.dev/pdufa/rp-l102): Fanconi Anemia Complementation Group A
- [Rp-l301](https://sec-api.dev/pdufa/rp-l301): Pyruvate Kinase Deficiency

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/rckt/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RCKT catalysts: ROCKET PHARMACEUTICALS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/rckt/catalysts

```bibtex
@misc{secapidev_companies_rckt_catalysts_20261116,
  title        = {RCKT catalysts: ROCKET PHARMACEUTICALS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/rckt/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_rckt_catalysts_20261116","title":"RCKT catalysts: ROCKET PHARMACEUTICALS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/rckt/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
